Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-498-0020
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.59 million
Profitability
Miscellaneous
Employees86
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions
What is Mersana Therapeutics' stock symbol?
Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."
How were Mersana Therapeutics' earnings last quarter?
Mersana Therapeutics Inc (NASDAQ:MRSN) posted its quarterly earnings data on Thursday, August, 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.38) by $0.02. The firm had revenue of $0.20 million for the quarter, compared to the consensus estimate of $1.08 million. Mersana Therapeutics had a negative return on equity of 51.13% and a negative net margin of 77.78%. View Mersana Therapeutics' Earnings History.
When is Mersana Therapeutics' next earnings date?
What price target have analysts set for MRSN?
6 brokers have issued 1-year price targets for Mersana Therapeutics' shares. Their forecasts range from $12.00 to $16.00. On average, they expect Mersana Therapeutics' share price to reach $14.00 in the next twelve months. This suggests a possible upside of 665.0% from the stock's current price. View Analyst Price Targets for Mersana Therapeutics.
What is the consensus analysts' recommendation for Mersana Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mersana Therapeutics.
Has Mersana Therapeutics been receiving favorable news coverage?
News articles about MRSN stock have trended negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mersana Therapeutics earned a coverage optimism score of -2.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Mersana Therapeutics.
Who are some of Mersana Therapeutics' key competitors?
Some companies that are related to Mersana Therapeutics include Prothena (PRTA), resTORbio (TORC), OptiNose (OPTN), DURECT (DRRX), Atreca (BCEL), Avid Bioservices (CDMO), Assembly Biosciences (ASMB), Minerva Neurosciences (NERV), Theratechnologies (THERF), BIOFRONTERA AG/ADR (BFRA), Protagonist Therapeutics (PTGX), Albireo Pharma (ALBO), Kindred Biosciences (KIN), OvaScience (OVAS) and Ardelyx (ARDX).
What other stocks do shareholders of Mersana Therapeutics own?
Who are Mersana Therapeutics' key executives?
Mersana Therapeutics' management team includes the folowing people:
- Ms. Anna Protopapas, Pres, CEO & Director (Age 55)
- Mr. David A. Spellman, Chief Financial Officer (Age 42)
- Dr. Timothy B. Lowinger, Sr. VP & Chief Scientific Officer (Age 55)
- Mr. Mikhail Papisov Ph.D., Co-Founder
- Ms. Sarah Carmody, Exec. Director of Investor Relations & Corp. Communications
When did Mersana Therapeutics IPO?
(MRSN) raised $75 million in an initial public offering on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Mersana Therapeutics' major shareholders?
Mersana Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.00%), Boxer Capital LLC (4.36%), Vanguard Group Inc. (3.98%), EcoR1 Capital LLC (2.91%), JPMorgan Chase & Co. (1.71%) and Point72 Asset Management L.P. (1.39%). Company insiders that own Mersana Therapeutics stock include Enterprise Associates 14 New and Timothy B Lowinger. View Institutional Ownership Trends for Mersana Therapeutics.
Which institutional investors are selling Mersana Therapeutics stock?
Which institutional investors are buying Mersana Therapeutics stock?
MRSN stock was acquired by a variety of institutional investors in the last quarter, including Boxer Capital LLC, BlackRock Inc., Vanguard Group Inc., Jacobs Levy Equity Management Inc., Morgan Stanley, Marshall Wace LLP, D. E. Shaw & Co. Inc. and Panagora Asset Management Inc.. View Insider Buying and Selling for Mersana Therapeutics.
How do I buy shares of Mersana Therapeutics?
Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Mersana Therapeutics' stock price today?
One share of MRSN stock can currently be purchased for approximately $1.83.
How big of a company is Mersana Therapeutics?
Mersana Therapeutics has a market capitalization of $87.33 million and generates $10.59 million in revenue each year. The company earns $-64,260,000.00 in net income (profit) each year or ($2.79) on an earnings per share basis. Mersana Therapeutics employs 86 workers across the globe.View Additional Information About Mersana Therapeutics.
What is Mersana Therapeutics' official website?
How can I contact Mersana Therapeutics?
Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]
MarketBeat Community Rating for Mersana Therapeutics (NASDAQ MRSN)
MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote "Outperform" if you believe MRSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRSN will underperform the S&P 500 over the long term. You may vote once every thirty days.
